… of levodopa should result in a reduction of side effects (dyskinesia: uncontrolled movements when levels are too high) … disease symptoms should have an added benefit of reducing dyskinesia and akinesia that are caused by current levodopa … subset (IPX066 vs. ER LD), “on” time without troublesome dyskinesia was significantly longer with IPX066 than with ER …

… a receptor) are capable of reducing levodopa-induced dyskinesias. However, current 5-HT1A agonists are poorly … region of the brain. These receptors mediate reductions in dyskinesia, depression and cognitive effects in pre-clinical … improve control of motor symptoms and simultaneously avoid dyskinesias. Such a strategy may also improve the mood …

… in the brain may be important in the development of dyskinesias in PD. Project Description :  Six PD subjects with dyskinesia, 6 early-untreated PD subjects and 6 healthy subjects will undergo dyskinesia ratings and imaging evaluation using 18F-PEB PET …

… actions of low-dose levodopa therapy and reduce adverse dyskinesias. To this end, we tested a small-molecule … for its ability to reverse akinesia and attenuate motor dyskinesias in a rodent model of PD. PD models treated with … dosing conditions for our PDE1 inhibitor in primates. Motor dyskinesias will be elicited in MPTP-treated models by …

… and durable improvement in motor function without worsening dyskinesia in Parkinson’s patients. Results from prior … in OFF time without an increase in time ON with dyskinesia were recorded by patients. CVT-301 was generally … Boston Globe Civitas Therapeutics Announces MJFF Grant … Dyskinesia … Complications of Treatment … Symptomatic … …

… actions of low-dose levodopa therapy and reduce adverse dyskinesias. To this end, we tested a small-molecule … for its ability to reverse akinesia and attenuate motor dyskinesias in a pre-clinical model of PD. This model … optimal dosing conditions for our PDE1 inhibitor. Motor dyskinesias will be elicited in an MPTP-treated pre-clinical …